New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 16, 2013
09:22 EDTMNKDSummer Street says 'suspicious' of MannKind AFFINITY trial
Summer Street says it has become "suspicious" of the results from MannKind's AFFINITY trial since the company released data on only two of three arms of the study. The firm says MannKind released the results on the injectable insulin and Dreamboat arms but withheld the results on the Medtone C-arm, which the firm says is "unprecedented." Summer Street does not have an official rating on shares of MannKind.
News For MNKD From The Last 14 Days
Check below for free stories on MNKD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
06:06 EDTMNKDStocks with implied volatility below IV index mean; AGN MNKD
Stocks with implied volatility below IV index mean; Allergan (AGN) 32, MannKind (MNKD) 73 according to iVolatility.
April 22, 2014
06:09 EDTMNKDStocks with implied volatility below IV index mean; NBG MNKD
Subscribe for More Information
April 21, 2014
06:14 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
April 17, 2014
03:54 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Stocks with implied volatility below IV index mean; Questcor (QCOR) 47, MannKind (MNKD) 82 according to iVolatility.
April 16, 2014
06:23 EDTMNKD Stocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
April 15, 2014
06:04 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
April 14, 2014
05:54 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Stocks with implied volatility below IV index mean; Questcor (QCOR) 44, MannKind (MNKD) 83 according to iVolatility.
April 11, 2014
10:46 EDTMNKDOptions with decreasing implied volatility: MNKD QCOR NQ WWE BBBY
06:04 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
April 10, 2014
12:29 EDTMNKDMannKind retreats after potential rival starts IPO process
Shares of drug maker MannKind (MNKD) are falling after a potential competitor, Dance Biopharm, sought to launch an initial public offering. WHAT'S NEW: Dance Biopharm filed papers with the SEC to raise $75M through an IPO last night. Like Mannkind, Dance has developed an inhaled insulin product that is supposed to treat diabetes. Dance's lead product, Dance 501, is designed to deliver liquid insulin through a small, handheld electronic inhaler, Dance stated in its IPO application. The company plans to launch a Phase III trial of the product in early 2015 and eventually seek regulatory approval of the product in the EU, U.S., and China. MannKind's AFREZZA, which is designed to deliver insulin through an inhaler, is currently under review for approval by the FDA. PRICE ACTION: In early afternoon trading, MannKind sank 30c, or 4.3%, to $6.70.
11:03 EDTMNKDOptions with decreasing implied volatility: MNKD QCOR MU KMX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use